Daniel Lynch, Director at Blueprint Medicines Corp (BPMC), sold 6,600 shares at $63.25 ($420K) on 2017-11-15, disclosed to the SEC on 2017-11-17.
Open-market sale of $420k BPMC by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $62.59 | 1,200 | $75K | 17.9% |
| 2 | $63.25 | 2,200 | $139K | 33.2% |
| 3 | $64.15 | 1,600 | $103K | 24.5% |
| 4 | $64.15 | 1,600 | $103K | 24.5% |
| Total | $63.57 avg | 6,600 | $420K | 100% |
| Filing → |
| SWTX | SELL | 2025-02-12 | $15.4M | — | Filing → |
| BPMC | SELL | 2018-02-16 | $1.0M | — | Filing → |
| BPMC | SELL | 2018-02-14 | $2.6M | — | Filing → |